ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer
University of California, Los Angeles (UCLA), Health SciencesA study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant survival benefits for patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.